. .

 
Zuruecksetzen

Suchergebnis - Bristol Myers Squib

Zeit Titel
27.09 22:17MÄRKTE USA/Uneinheitlich nach Inflationsdaten - Dow mit Rekordhoch
27.09 18:12MÄRKTE USA/Uneinheitlich nach Inflationsdaten - Dow mit Rekordhoch
27.09 15:44MÄRKTE USA/Börsen nach Inflationsdaten gut behauptet gestartet
27.09 15:08MÄRKTE USA/Wall Street nach Inflationsdaten etwas fester erwartet
27.09 12:34MARKT USA/Börsen knapp behauptet erwartet - Inflationsdaten im Blick
27.09 08:12dpa-AFX: *BRISTOL-MYERS BEI TG +4,3% VS NYSE - FDA-ZULASSUG FÜR COBENFY
27.09 03:31dpa-AFX: Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment
25.09 13:47dpa-AFX: 2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study
25.09 13:13dpa-AFX: *2SEVENTY, BRISTOL MYERS TO DISCONTINUE ENROLLMENT IN PHASE 3 KARMMA-9 STUDY
16.09 11:59dpa-AFX: *IMMATICS UNVEILS PROMISING PHASE 1 DATA FOR TCER IMA401 TARGETING MAGEA4/8
10.09 23:51dpa-AFX: *BRISTOL-MYERS SQUIBB CO. (BMY) DECLARES QUARTERLY DIVIDEND OF $ 0.60, RECORD DATE 10/4/2024
06.09 14:34dpa-AFX: Bristol-Myers Squibb To Present At Wells Fargo Healthcare Conference; Webcast At 9:30 AM ET
05.09 18:09dpa-AFX: Bristol-Myers Squibb To Present At Morgan Stanley Healthcare Conference; Webcast At 1:05 PM ET
05.09 02:59dpa-AFX: Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada
02.09 04:35dpa-AFX: Biotech Stocks Facing FDA Decision In September 2024
21.08 13:57dpa-AFX: Bristol Myers : FDA Accepts SBLA For First-Line Treatment Of Unresectable Hepatocellular Carcinoma
21.08 13:43dpa-AFX: *BRISTOL MYERS SQUIBB: FDA ACCEPTS SBLA FOR OPDIVO + YERVOY FOR 1ST-LINE TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
19.08 16:03dpa-AFX: EMA Validates Bristol Myers Squibb's Application For CAR T Cell Therapy Breyanzi
19.08 15:03dpa-AFX: *EMA VALIDATES BRISTOL MYERS SQUIBB'S APPLICATION FOR CAR T CELL THERAPY BREYANZI FOR R/R FOLLICULAR LYMPHOMA
16.08 12:28MARKT USA/Wall Street nach Rally behauptet erwartet

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH